MARKET IS OPEN
Loading latest tickers...

Market Indices

S&P 500
$7,801.77
-0.22%
NASDAQ 100
$31,160.08
-0.21%
DOW JONES
$51,180.00
-0.66%
NASDAQ Composite
$27,538.69
-0.22%
RUSSELL 2000
$2,777.00
-1.29%
CBOE VIX
$15.08
+0.47%

Sector Heatmap

Technology-0.30%
Financials-0.48%
Healthcare+1.03%
Consumer Cycl-0.32%
Consumer Staples-0.12%
Energy-0.58%
Industrials-2.18%
Materials-1.51%
Real Estate-1.29%
Utilities-0.02%
Comm Services-0.35%

RCUS — Arcus Biosciences, Inc.

NYSE

Arcus Biosciences, Inc.

CompareBack to Screener
$24.52
+0.24(+0.99%)
O
24.23
H
24.85
L
23.90
V
1.6M
⏱️ End-of-day dataAs of Oct 7, 2026
OverviewStatisticsFinancialsHistorical DataOptionsDividend HistoryNewsChart

Chart

About RCUS

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateMar 15, 2018
Employees601
Stock ExchangeNYSE
Ticker SymbolRCUS
Websitehttps://www.arcusbio.com

Key Financial Statistics

Market Cap$3.11B
P/E RatioN/A
Dividend YieldNone
EPSN/A
BetaN/A
52-Week Range$14.18 - $31.74
52-Week Avg Volume1.43M
VWAP$24.53
Transactions15,368
Total Recorded Bars2,153 days